I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

*S*erpine1 plasminogen activator inhibitor-1 (PAI-1, 4G/5G) member is the principal inhibitor of tissue plasminogen activator and urokinase, and hence is an inhibitor of fibrinolysis. Defects in this gene \[*Serpine1* (PAI-1, 4G/5G) variant\] are the cause of PAI-1 excess, and high concentrations of this gene product inhibit fibrinolysis and cause thrombophilia. Alternatively, spliced transcript variants encoding different isoforms have been found for this gene. Defects in *serpine1* are the main cause of PAI-1 excess, which is characterized by thrombophilia.\[[@ref1]\] Plasminogen activator gets inhibited leading to decreased plasmin and less fibrin dissolution and impaired invasion of extracellular matrix and altered cell migration.\[[@ref2]\]

This case is highlights the role of low molecular weight heparin in implantation failure. Laser-assisted hatching in frozen embryo transfer may help in patients of PAI excess due to *serpine* gene polymorphism. Embryo transfer Media containing hyaluronic acid may have a role in cases of genetic defects of defective extracellular matrix degradation.

C[ASE]{.smallcaps} H[ISTORY]{.smallcaps} {#sec1-2}
========================================

Mrs. R, aged 30, had primary infertility for 9 years with 6 intrauterine insemination (IUI) failures. Her anti mullerian hormone (AMH) was 4.94 ng/ml. Hysteroscopy study of endometrium was normal \[[Figure 1](#F1){ref-type="fig"}\]. Thrombophilia gene panel was investigated.

![Hysteroscopy of uterine endometrium and cavity](JHRS-10-135-g001){#F1}

Patient had SERPINE1-816 5G/4G heterozygous genotype with one normal allele and one variant allele. Ovulation induction was done with GnRh agonist long mini-dose protocol Buserelin 0.001 mg/kg (Suprefact Injection Solution, Sanofi-Aventis New Zealand Limited, Ellerslie Auckland, New Zealand) long protocol started from day 21. Buserelin dose was decreased to 0.005 mg/kg on day 1. Recombinant FSH 150 IU was started on day 1. FSH was stepped down to 112.5 IU after day 8 when follicles were 14 mm. Ovulation trigger was given with recombinant HCG 250 µg on day 12 when multiple follicles of 17 to 20 mm were seen. Ovum pick up was done after 40 h of trigger. Thirteen eggs were collected. Patient was put on Cabergolin orally 0.05 mg at bedtime for 8 days (Generic Dostinex, Caberlin by Sun Pharma, Mumbai, Maharashtra) to prevent OHSS.

In the next cycle, the endometrium was prepared with estrogens. Four frozen day 3 embryos at 8-cell stage (Grade 1) were transferred on day 17 of estrogen and day 3 of progesterone after Laser-assisted hatching \[[Figure 2](#F2){ref-type="fig"}\]. EmbryoGlue (Vitrolife, Göteborg, Sweden) (containing hyaluronic acid) in embryo transfer media was used to prevent implantation failure. Luteal phase support was given. She was put on enoxaparin from the day of embryo transfer. The patient was on strict monitoring as this gene is also associated with preeclampsia during pregnancy. At 34 weeks, she developed gestational hypertension. There was no proteinuria. The blood pressure was controlled with rest and diet. She delivered a live healthy baby by cesarean section at term. Postpartum blood pressure was normal.

![Laser assisted hatching helps in implantation as the freeze all protocol may lead to Zona Hardening](JHRS-10-135-g002){#F2}

D[ISCUSSION]{.smallcaps} {#sec1-3}
========================

The polymerase chain reaction (PCR) test categorizes individuals for risk of thrombophilia by genotyping Factor V (Leiden, 1691G\>A), Factor II prothrombin (20210G\>A), and SERPINE1 (PAI-1, 4G/5G) variations using allele-specific real-time PCR. The method has almost 100% analytical accuracy and sensitivity. Variants or genes other than the ones mentioned are not tested. Very rarely the test may give inconclusive, clinical false positive, or false negative results. (BSH 2011, Clinical guideline in British Journal of Haematology; ASRM 2012, Committee Opinion in Fertility and Sterility; RCOG 2011, Green-top Guideline 17)

Thrombophilia, or hypercoagulability, refers to the increased tendency of blood to clot. Among the frequent causes of inherited thrombophilia are mutations in Factor V, Factor II prothrombin, and SERPINE1.\[[@ref3][@ref4]\] Pregnancy is by itself a thrombophilia condition. The presence of these mutations increases clotting events, which may lead to recurrent pregnancy loss (early and/or late), preeclampsia (high blood pressure), intrauterine growth restriction, and stillbirth. About 15 to 60% of infertile women were found to have one or more mutations predisposing to thrombophilia. Other contributors to thrombophilia include protein C, protein S, antithrombin, and antiphospholipid antibodies, which may be tested by protein-based assays. Close monitoring and thromboprophylaxis in these women may be beneficial during pregnancy.

This polymorphism is also associated with preeclampsia. Meta-analysis of 11 studies involving 1297 preeclampsia cases and 1791 controls found a significant association between the SERPINE1-675 4G/5G polymorphism and preeclampsia for the recessive genetic model \[odds ratio (OR) = 1.36, 95% confidence interval (CI): 1.13--1.64, *P* = 0.001\], a robust finding according to sensitivity analysis.\[[@ref5][@ref6][@ref7]\]

Thrombophilia gene profile (including *serpine1*) is a cost effective method to be included in patients diagnosed to have recurrent clinical and subclinical pregnancy losses. Plasmin has a role in fibrin degradation, extracellular matrix remodeling, and cell migration. Genetic factors cannot be modified but adding adjuvants to improve the microenvironment of embryo--endometrial interphase can help. Recurrent implantation failure and placental bed disorders, resulting in preeclampsia, may have a common genetic basis.
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